Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | HPGD | P15428 | 3/20 | 0.71 |
| ▸ | GLA | P06280 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.71 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.71 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 6/20 | 0.67 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241976 | 0.89 | SMN1; SMN2 (0.71) | KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL4799251 | 0.87 | KDM4E (0.77) | KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL1987724 | 0.84 | APP (0.72) | GLAGAAAPP | |
| SCHEMBL12422175 | 0.84 | APP (0.64) | KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL1347142 | 0.83 | SMN1; SMN2 (1.00) | KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL30466257 | 0.83 | SMN1; SMN2 (1.00) | KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL29576858 | 0.83 | SMN1; SMN2 (1.00) | KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL3064950 | 0.83 | APP (0.60) | KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL7836371 | 0.82 | APP (0.75) | KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL2136609 | 0.82 | MAPT (0.73) | KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101420950-B | Treatment of duchenne muscular dystrophy | SUMMIT CORP PLC | 2012-04-18 | — | — | CN | disclosed |
| CN-101678107-A | Pharmaceutical composition for treating Duchenne muscular dystrophy | SUMMIT CORP PLC | 2010-03-24 | — | — | CN | disclosed |
| CN-101420950-A | Treatment of Duchenne muscular dystrophy | SUMMIT CORP PLC (GB) | 2009-04-29 | — | — | CN | disclosed |
| EP-1910349-A1 | 2-ARYLBENZOTHIAZOLES AND USES THEREOF | 4SC AG (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009524-A1 | 2-ARYLBENZOTHIAZOLES AND USES THEREOF | 4SC AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | 4SC AG (DE) | 2007-01-25 | — | — | US | disclosed |
| EP-1746096-A1 | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer | 4SC AG (DE) | 2007-01-24 | — | — | EP | disclosed |
| EP-1746096-A1 | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer | 4SC AG (DE) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | NR2E1, NR2E3, NR0B2 | KDM4E 2243/4885SMN1; SMN2 1665/4885ALDH1A1 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.